Acute Lung Injury: From Molecular Circuits to System-Level Therapeutics

Abstract

Acute lung injury (ALI) and its severe manifestation, acute respiratory distress syndrome (ARDS), remain critical conditions with persistently high mortality. The failure to develop effective pharmacotherapies stems largely from reductionist approaches focused on isolated linear pathways. This review synthesizes recent breakthroughs redefining ALI as dysregulation of integrated pathological networks spanning immunity, metabolism, and cell death. We systematically analyze three interconnected core circuits: cGAS–STING as a central danger signal integrator, immunometabolic reprogramming as fuel for sustained inflammation, and the programmed cell death network—particularly PANoptosis—as executor of tissue damage. We further elucidate how ALI manifests as a multiorgan communication disorder, with the brain and gut actively shaping pulmonary inflammation. The convergence of single-cell technologies, multiomics profiling, and computational modeling has deconstructed ARDS heterogeneity into clinically actionable endotypes (hyperinflammatory C1, hypoinflammatory C2) with differential treatment responses. This network-based understanding is catalyzing a therapeutic shift toward rationally designed poly-pharmacology, precision immunotherapies, and advanced platforms integrating smart nanomaterials with endogenous systems. By embracing this holistic perspective, we chart a course toward mechanism-based, personalized interventions that move beyond supportive care to genuine disease modification.

Keywords

acute lung injury (ALI) / endotypes / immunometabolism / network medicine / PANoptosis

References

[1] L. D. J. Bos and L. B. Ware, “Acute respiratory Distress Syndrome: Causes, Pathophysiology, and Phenotypes,” Lancet 400, no. 10358 (2022): 1145–1156.

[2] N. J. Meyer and C. S. Calfee, “Acute respiratory Distress Syndrome,” Lancet 398, no. 10300 (2021): 622–637.

[3] K. D. Wick, L. B. Ware, and M. A. Matthay, “Acute respiratory Distress Syndrome,” Bmj 387 (2024): e076612.

[4] G. W. Williams, N. K. Berg, A. Reskallah, et al., “Acute Respiratory Distress Syndrome,” Anesthesiology 134, no. 2 (2021): 270–282.

[5] M. A. Matthay, Y. Arabi, A. C. Arroliga, et al., “A New Global Definition of Acute Respiratory Distress Syndrome,” American Journal of Respiratory and Critical Care Medicine 209, no. 1 (2024): 37–47.

[6] K. Bihlmaier, C. Willam, L. Herbst, et al., “Rapid Clinical Effects of Convalescent Plasma Therapy in Severe COVID-19 Acute respiratory Distress Syndrome (ARDS),” Intensive Care Medicine 51, no. 4 (2025): 793–795.

[7] R. Xie, D. Tan, B. Liu, et al., “Acute respiratory Distress Syndrome (ARDS): From Mechanistic Insights to Therapeutic Strategies,” MedComm 6, no. 2 (2025): e70074.

[8] G. Bellani, J. G. Laffey, T. Pham, et al., “Epidemiology, Patterns of Care, and Mortality for Patients with Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries,” Jama 315, no. 8 (2016): 788–800.

[9] Z. Geng, A. M. Hynes, A. M. Moren, et al., “Acute Respiratory Distress Syndrome in Trauma 2007–2019: Comprehensive Patient and Center-Level Retrospective Cohort Analysis,” Critical Care Medicine 54, no. 1 (2026): 76–86.

[10] Y. Sakr, B. François, J. Solé-Violan, et al., “Temporal Changes in the Epidemiology, Management, and Outcome From Acute respiratory Distress Syndrome in European Intensive Care Units: A Comparison of Two Large Cohorts,” Critical Care 25, no. 1 (2021): 87.

[11] V. Parcha, R. Kalra, S. P. Bhatt, et al., “Trends and Geographic Variation in Acute Respiratory Failure and ARDS Mortality in the United States,” Chest 159, no. 4 (2021): 1460–1472.

[12] J. P. Reilly, Z. Zhao, M. G. S. Shashaty, et al., “Exposure to Ambient Air Pollutants and Acute respiratory Distress Syndrome Risk in Sepsis,” Intensive Care Medicine 49, no. 8 (2023): 957–965.

[13] H. Wang, Y. Wei, C. T. Hung, et al., “Association of nirmatrelvir-ritonavir With Post-acute Sequelae and Mortality in Patients Admitted to Hospital With COVID-19: A Retrospective Cohort Study,” Lancet Infectious Diseases 24, no. 10 (2024): 1130–1140.

[14] E. Papoutsi, K. Gkirgkiris, V. Tsolaki, et al., “Association between Baseline Driving Pressure and Mortality in Very Old Patients With Acute Respiratory Distress Syndrome,” American Journal of Respiratory and Critical Care Medicine 210, no. 11 (2024): 1329–1337.

[15] B. O'Gara and D. Talmor, “Perioperative Lung Protective Ventilation,” Bmj 362 (2018): k3030.

[16] T. G. Weiser, A. B. Haynes, G. Molina, et al., “Estimate of the Global Volume of Surgery in 2012: An Assessment Supporting Improved Health outcomes,” Lancet 385, no. Suppl 2 (2015): S11.

[17] G. Dorland, M. Gama de Abreu, S. N. T. Hemmes, et al., “Intraoperative Driving Pressure-Guided High PEEP vs Standard Low PEEP for Postoperative Pulmonary Complications,” Jama 335, no. 8 (2026): 693–702.

[18] A. Fernandez-Bustamante, G. Frendl, J. Sprung, et al., “Postoperative Pulmonary Complications, Early Mortality, and Hospital Stay Following Noncardiothoracic Surgery: A Multicenter Study by the Perioperative Research Network Investigators,” JAMA Surgery 152, no. 2 (2017): 157–166.

[19] A. Fernandez-Bustamante, J. Klawitter, J. E. Repine, et al., “Early Effect of Tidal Volume on Lung Injury Biomarkers in Surgical Patients With Healthy Lungs,” Anesthesiology 121, no. 3 (2014): 469–481.

[20] W. Ma, S. Tang, P. Yao, et al., “Advances in Acute respiratory Distress Syndrome: Focusing on Heterogeneity, Pathophysiology, and Therapeutic Strategies,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 75.

[21] M. A. Matthay, Y. M. Arabi, E. R. Siegel, et al., “Phenotypes and Personalized Medicine in the Acute respiratory Distress Syndrome,” Intensive Care Medicine 46, no. 12 (2020): 2136–2152.

[22] H. Li, T. Liu, Y. Wang, et al., “Paraventricular Nucleus CRH Neurons Regulate Acute Lung Injury via Sympathetic Nerve-neutrophil Axis,” Nature Communications 16, no. 1 (2025): 8870.

[23] J. Wang, X. Xue, X. Zhao, et al., “Forsythiaside A Alleviates Acute Lung Injury by Inhibiting Inflammation and Epithelial Barrier Damages in Lung and Colon Through PPAR-γ/RXR-α Complex,” Journal of Advanced Research 60 (2024): 183–200.

[24] Y. H. Wang, Z. Z. Yan, S. D. Luo, et al., “Gut Microbiota-derived Succinate Aggravates Acute Lung Injury After Intestinal Ischaemia/Reperfusion in Mice,” European Respiratory Journal 61, no. 2 (2023): 2200840.

[25] S. Tang, J. Zhang, Z. He, et al., “Microbial Metabolite Oxindole Curbs Acute Lung Injury by Suppressing CXCL13,” Proceedings of the National Academy of Sciences of the United States of America 123, no. 9 (2026): e2519332123.

[26] M. Ziaka and A. Exadaktylos, “Gut-derived Immune Cells and the Gut-lung Axis in ARDS,” Critical Care 28, no. 1 (2024): 220.

[27] C. E. Evans, S. P. Behera, X. Zhang, et al., “The Unexpected Protective Role of Thrombosis in Lung Injury via Endothelial Alox15,” Circulation Research 138, no. 1 (2026): e326357.

[28] H. Hong, Y. Wu, Y. Li, et al., “Endothelial PPARδ Ablation Exacerbates Vascular Hyperpermeability via STAT1/CXCL10 Signaling in Acute Lung Injury,” Circulation Research 136, no. 7 (2025): 735–751.

[29] N. Ramadas, K. Lowder, J. Dutton, et al., “Targeting PAR1 Biased Signaling with Parmodulin Reduces Thromboinflammation and Acute Lung Injury in Sickle Cell Disease,” Blood Advances 10, no. 7 (2026): 2351–2362.

[30] D. Chiumello, S. Coppola, P. L. Silva, et al., “Bedside Ventilatory Settings Guided by respiratory Mechanics in Acute respiratory Distress Syndrome,” Annals of Intensive Care 15, no. 1 (2025): 189.

[31] A. Servetti, D. Battaglini, N. A. Patroniti, et al., “Optimising Positive End-expiratory Pressure in Acute respiratory Distress Syndrome: A Narrative Review of Approaches to Titration,” British Journal of Anaesthesia 136, no. 5 (2026): 1472–1481.

[32] B. Zhang, P. Xu, and A. Ablasser, “Regulation of the cGAS-STING Pathway,” Annual Review of Immunology 43, no. 1 (2025): 667–692.

[33] Z. Zhang and C. Zhang, “Regulation of cGAS-STING Signalling and Its Diversity of Cellular Outcomes,” Nature Reviews Immunology 25, no. 6 (2025): 425–444.

[34] A. Decout, J. D. Katz, S. Venkatraman, and A. Ablasser, “The cGAS-STING Pathway as a Therapeutic Target in Inflammatory Diseases,” Nature Reviews Immunology 21, no. 9 (2021): 548–569.

[35] J. Rebetz, H. Cederholm, D. McGauran, et al., “Mitochondrial DNA via Recipient TLR9 Acts as a Potent First Hit in Murine Transfusion-related Acute Lung Injury,” Blood 146, no. 20 (2025): 2479–2490.

[36] Y. Bai, X. Zhan, Q. Zhu, et al., “ATG16L1 restrains Macrophage NLRP3 Activation and Alveolar Epithelial Cell Injury During Septic Lung Injury,” Clinical and Translational Medicine 15, no. 4 (2025): e70289.

[37] Y. Shi, Y. Liang, Y. Chen, and Z. Li, “Role of IRGM in Acute Lung Injury: Inducing Mitophagy and Inactivating cGAS-STING Signaling to Improve Lipopolysaccharide-induced Alveolar Epithelial Barrier Dysfunction,” Prostaglandins & Other Lipid Mediators 180 (2025): 107026.

[38] Z. Huang, C. Wei, H. Xie, et al., “Treating Acute Lung Injury Through Scavenging of Cell-free DNA by Cationic Nanoparticles,” Materials Today Bio 29 (2024): 101360.

[39] Z. Chen, X. Liu, K. Zuo, et al., “TAT-PBX1 Fusion Protein Alleviates LPS-induced Acute Lung Injury via AMPK-TFAM Signaling Activation,” Molecular Therapy 33, no. 12 (2025): 6537–6553.

[40] M. Zhao, X. Xie, Y. Ding, et al., “Glabridin Protects Against Paraquat-induced Acute Lung Injury by Targeting ME1 to Mitigate Oxidative Stress, Mitochondrial Dysfunction, and cGAS-STING Activation,” Free Radical Biology & Medicine 235 (2025): 317–334.

[41] Y. Chen, D. Wu, Q. Li, et al., “Aminoguanidine-assembled Functional DNA Tetrahedron Alleviates Acute Lung Injury by Targeting the cGAS-STING Signaling Pathway,” Materials Today Bio 32 (2025): 101760.

[42] X. Qin, Z. Fu, L. Wu, et al., “Regulation of cGAS-STING Pathway With Inhalable Nanozyme in Acute Lung Injury,” Biomaterials 324 (2026): 123521.

[43] H. Wang, C. Fan, X. Chen, et al., “Pyruvate Kinase M2 Nuclear Translocation Regulate Ferroptosis-Associated Acute Lung Injury in Cytokine Storm,” Inflammation 47, no. 5 (2024): 1667–1684.

[44] C. C. Chen, S. Q. Huang, P. H. Chen, et al., “Integration of Bioinformatics and Experiments to Identify Mitochondrial Metabolism and Immune Infiltration Characterization in Lung Injury and Post-Injury Lung Fibrosis,” FASEB Journal 40, no. 2 (2026): e71485.

[45] X. Liu, R. Zhang, L. Fan, et al., “Targeting Immunometabolism Against Acute Lung Injury,” Clinical Immunology 249 (2023): 109289.

[46] D. Yuan, F. Yang, L. Hou, et al., “PFKFB2-Driven Glycolysis Promotes Dendritic Cell Maturation and Exacerbates Acute Lung Injury,” Advanced Science 12, no. 37 (2025): e02428.

[47] M. Jiang, Y. Yang, Y. Zhang, et al., “Covalent Targeting GAPDH by Pudilan Formula and baicalein Suppresses Macrophage Warburg Effect to Alleviate Acute Lung Injury,” Phytomedicine 151 (2026): 157727.

[48] M. Wang, D. Wu, X. Liao, et al., “CPT1A-IL-10-mediated Macrophage Metabolic and Phenotypic Alterations Ameliorate Acute Lung Injury,” Clinical and Translational Medicine 14, no. 8 (2024): e1785.

[49] Z. Sun, H. Meng, X. Wang, et al., “Trained Immunity Attenuated Acute Lung Injury by Activating Alveolar Macrophages via AKT2-PDK1 Axis-mediated Metabolic Reprogramming,” Journal of Translational Medicine 23, no. 1 (2025): 1412.

[50] X. Li, Y. Long, Y. Zhu, et al., “Endothelial-Derived CCL7 Promotes Macrophage Polarization and Aggravates Septic Acute Lung Injury via CCR1-Mediated STAT1 Succinylation,” Advanced Science 12, no. 38 (2025): e06209.

[51] M. Luo, A. Al-Waqeerah, and L. Gao, “Iron Homeostasis and Macrophage Polarization in Pulmonary Fibrosis: Mechanisms and Therapeutic Perspectives,” Frontiers in Immunology 16 (2025): 1742761.

[52] J. Tang, M. Yan, M. Li, et al., “From “Metabolic Storm” to “Immune Paralysis”: The Dynamic Evolution of Macrophages and Metabolism Reprogramming in ARDS,” Frontiers in Immunology 16 (2025): 1738713.

[53] C. Xie, M. Yalikun, Z. Ruan, et al., “Macrophage Immunometabolism in Pulmonary Homeostasis and Chronic Lung Diseases,” International Journal of Biological Sciences 21, no. 15 (2025): 6580–6598.

[54] Y. He, W. Xie, H. Zhou, et al., “Dexmedetomidine Alleviates Sepsis-induced Acute Lung Injury by Inhibiting M1 Macrophage Polarization via Inhibition of PKM2-mediated Warburg Effect,” Biochemical Pharmacology 241 (2025): 117130.

[55] K. P. Chung, C. N. Cheng, Y. J. Chen, et al., “Alveolar Epithelial Cells Mitigate Neutrophilic Inflammation in Lung Injury Through Regulating Mitochondrial Fatty Acid Oxidation,” Nature Communications 15, no. 1 (2024): 7241.

[56] J. Xu, Y. Wang, W. Mao, et al., “Metabolic Interplay in Acute Lung Injury: PARK7 Integrates FADS1/2-Dependent PUFA Metabolism and H3K14 Lactylation to Attenuate Endothelial Ferroptosis and Dysfunction,” Advanced Science 12, no. 46 (2025): e08725.

[57] Y. Deng, Y. Qiu, X. Li, et al., “PDK4-driven Lactate Accumulation Facilitates LPCAT2 Lactylation to Exacerbate Sepsis-induced Acute Lung Injury,” Cell Death Differentiation 33, no. 3 (2025): 557–573.

[58] Z. Lu, P. Fang, S. Li, et al., “Lactylation of Histone H3k18 and Egr1 Promotes Endothelial Glycocalyx Degradation in Sepsis-Induced Acute Lung Injury,” Advanced Science 12, no. 7 (2025): e2407064.

[59] H. Zhu, L. Zhou, W. Bao, et al., “Acetate Produced by the Interaction Between Houttuynia Pectin and Phocaeicola Vulgatus Alleviated H1N1-induced Acute Lung Injury in Mice Through the GPR43/JAK2/STAT3 Pathway,” Carbohydrate Polymers 369 (2025): 124280.

[60] T. Pan, M. Li, J. Guo, et al., “Bacillus Safensis From Sauerkraut Alleviates Acute Lung Injury Induced by Methicillin-Resistant Staphylococcus aureus Through the Regulation of M2 Macrophage Polarization via Its Metabolite Esculin,” Journal of Agricultural and Food Chemistry 73, no. 1 (2025): 409–424.

[61] Z. Ren, Z. Zheng, and X. Feng, “Role of Gut Microbes in Acute Lung Injury/Acute respiratory Distress Syndrome,” Gut Microbes 16, no. 1 (2024): 2440125.

[62] L. Zheng, C. Liu, H. Wang, et al., “Intact Lung Tissue and Bronchoalveolar Lavage Fluid Are Both Suitable for the Evaluation of Murine Lung Microbiome in Acute Lung Injury,” Microbiome 12, no. 1 (2024): 56.

[63] M. Shan, S. Zhang, Z. Luo, et al., “Itaconate Promotes Inflammatory Responses in Tissue-resident Alveolar Macrophages and Exacerbates Acute Lung Injury,” Cell Metabolism 37, no. 8 (2025): 1750–1765.e7.

[64] R. Li, Y. Liu, G. Li, et al., “Chebulinic Acid From Chebulae Fructus Alleviates Influenza Virus-induced Acute Lung Injury by Inhibiting IDO1-Kyn Axis Activation,” Phytomedicine 148 (2025): 157362.

[65] W. Huang, G. Fu, Y. Wang, et al., “Immunometabolic Reprogramming of Macrophages With Inhalable CRISPR/Cas9 Nanotherapeutics for Acute Lung Injury Intervention,” Acta Biomaterialia 181 (2024): 308–316.

[66] M. Upadhyay, D. Nelson, M. Phillips, et al., “Regulation of Endothelial Cell Death in Inflammatory Lung Injury,” American Journal of Respiratory Cell and Molecular Biology 74, no. 5 (2026): 575–589, https://doi.org/10.1165/rcmb.2025-0443TR, Published online October 10, 2025.

[67] Q. Gao, X. Han, J. Wang, et al., “Crosstalk Between Mitochondrial Quality Control and Novel Programmed Cell Death in Pulmonary Diseases,” Biomedicine & Pharmacotherapy 189 (2025): 118335.

[68] J. Liao, Y. Liang, Z. Liu, et al., “Pyroptosis in Acute respiratory Distress Syndrome and Pulmonary Fibrosis,” Biomedicine & Pharmacotherapy 189 (2025): 118286.

[69] Y. Cai, L. Shang, F. Zhou, et al., “Macrophage Pyroptosis and Its Crucial Role in ALI/ARDS,” Frontiers in Immunology 16 (2025): 1530849.

[70] F. Wang, H. Deng, M. Zhou, et al., “Anti-PD-1 Exacerbates Bleomycin-induced Lung Injury in Mice via Caspase-3/GSDME-mediated Pyroptosis,” Cell Death & Disease 16, no. 1 (2025): 3.

[71] Y. Wang, T. Zhang, X. Gou, et al., “Rottlerin Inhibits PKCδ to Attenuate Pulmonary Fibrosis by Suppressing NLRC4/ASC-mediated Pyroptosis,” Phytomedicine 146 (2025): 157154.

[72] J. Yang, X. Huang, Q. Yu, et al., “Extracellular Vesicles Derived From M2-Like Macrophages Alleviate Acute Lung Injury in a miR-709-mediated Manner,” Journal of Extracellular Vesicles 13, no. 4 (2024): e12437.

[73] B. Li, J. Liu, W. He, et al., “Inhibition of Macrophage Inflammasome Assembly and Pyroptosis With GC-1 Ameliorates Acute Lung Injury,” Theranostics 15, no. 6 (2025): 2360–2374.

[74] B. Li, C. Xia, W. He, et al., “The Thyroid Hormone Analog GC-1 Mitigates Acute Lung Injury by Inhibiting M1 Macrophage Polarization,” Advanced Science 11, no. 44 (2024): e2401931.

[75] F. Jiang, J. Jiang, Y. Sun, et al., “Pelargonidin-3-O-galactoside Alleviates Acute Lung Injury Induced by Klebsiella pneumoniae by Targeting CD38-Mediated Pyroptosis,” Journal of Agricultural and Food Chemistry 73, no. 22 (2025): 13415–13426.

[76] W. Zhang, H. Yang, B. Sui, et al., “Ophiopogonin C Protects Against Acute Lung Injury by Fatal Sepsis Through Pyroptosis Macrophage,” Phytomedicine 142 (2025): 156698.

[77] A. Gan, H. Chen, F. Lin, et al., “Sanzi Yangqin Decoction Improved Acute Lung Injury by Regulating the TLR2-mediated NF-κB/NLRP3 Signaling Pathway and Inhibiting the Activation of NLRP3 Inflammasome,” Phytomedicine 139 (2025): 156438.

[78] Z. Chen, B. Lin, X. Yao, et al., “OAS3 Deubiquitination due to E3 Ligase TRIM21 Downregulation Promotes Epithelial Cell Apoptosis and Drives Sepsis-induced Acute Lung Injury,” International Journal of Biological Sciences 20, no. 14 (2024): 5594–5607.

[79] T. Wu, M. Ji, T. Li, and L. Luo, “The Molecular and Metabolic Landscape of Ferroptosis in respiratory Diseases: Pharmacological Aspects,” Journal of Pharmaceutical Analysis 15, no. 1 (2025): 101050.

[80] Y. Zheng, Y. Zhang, Y. Chen, et al., “Indoleamine 2,3-dioxygenase 1 Drives Epithelial Cells Ferroptosis in Influenza-induced Acute Lung Injury,” Redox Biology 81 (2025): 103572.

[81] H. T. Zhou, J. Huang, Y. K. Liu, et al., “The Emerging Role of Ferroptosis in the Pathological Development and Progression of Sepsis,” Military Medical Research 15, no. 1 (2025): 81.

[82] R. Li, L. Qin, J. Ren, et al., “Remimazolam Alleviates Acute Lung Injury by Inhibiting Ferroptosis: A Multi-omics System Pharmacology Approach With Experimental Validation,” European Journal of Medical Research 31, no. 1 (2026), https://doi.org/10.1186/s40001-026-03997-7, Published online February 12, 2026.

[83] M. Li, L. Hu, Q. Ke, et al., “Arginine Methyltransferase PRMT1 Promotes Ferroptosis Through EGR1/GLS2 Axis in Sepsis-related Acute Lung Injury,” Communication Biology 8, no. 1 (2025): 159.

[84] Z. Li, Y. Bu, C. Wang, et al., “Extracellular Vesicle-packaged GBP2 From Macrophages Aggravates Sepsis-induced Acute Lung Injury by Promoting Ferroptosis in Pulmonary Vascular Endothelial Cells,” Redox Biology 82 (2025): 103614.

[85] L. Tang, C. Yang, Y. Peng, et al., “YAP/Nrf2 Suppresses Ferroptosis to Alleviate Acute Lung Injury Induced by Intestinal Ischemia/Reperfusion,” Redox Biology 86 (2025): 103811.

[86] X. Fan, Y. Ai, G. Mu, et al., “Celastrol Attenuates Ferroptosis-mediated Intestinal Ischemia/Reperfusion-induced Acute Lung Injury via Hippo-YAP Signaling,” Phytomedicine 143 (2025): 156865.

[87] F. Su, X. Yan, X. Li, et al., “SLC38A1 Inhibits Ferroptosis of Alveolar Type II Epithelial Cells in Acute Lung Injury by Promoting Autophagic Degradation of Divalent Metal Transporter 1 (DMT1): An in Vivo and in Vitro Study,” Inflammation 49, no. 1 (2026): 25.

[88] H. X. Sha, Y. B. Liu, Y. L. Qiu, et al., “Neutrophil Extracellular Traps Trigger Alveolar Epithelial Cell Necroptosis Through the cGAS-STING Pathway During Acute Lung Injury in Mice,” International Journal of Biological Sciences 20, no. 12 (2024): 4713–4730.

[89] M. Zhang, L. Shang, F. Zhou, et al., “Dachengqi Decoction Dispensing Granule Ameliorates LPS-induced Acute Lung Injury by Inhibiting PANoptosis in Vivo and in Vitro,” Journal of Ethnopharmacology 336 (2025): 118699.

[90] H. Jin, S. Holland, A. Jha, et al., “DLL4+ neutrophils Promote Notch1-mediated Endothelial PANoptosis to Exacerbate Acute Lung Injury in Sepsis,” Journal of Clinical Investigation 135, no. 24 (2025): e194310.

[91] D. Wang, Y. Gong, Y. Chen, et al., “Lactate Attenuates PANoptosis and Enhances ZBP-1 Lactylation in Macrophages in Acute Lung Injury,” Frontiers in Immunology 16 (2025): 1648303.

[92] Z. Xu, K. Wang, H. Hu, et al., “Protective Effects of Exocarpium Citri Grandis Against Sepsis-induced Acute Lung Injury via PANoptosis Inhibition,” Frontiers in Nutrition 12 (2025): 1661404.

[93] T. Gong, Q. D. Wang, R. A. Loughran, et al., “Mechanism of Lactic Acidemia-promoted Pulmonary Endothelial Cells Death in Sepsis: Role for CIRP-ZBP1-PANoptosis Pathway,” Military Medical Research 11, no. 1 (2024): 71.

[94] H. Jin, M. Aziz, A. Murao, et al., “Antigen-presenting Aged Neutrophils Induce CD4+ T Cells to Exacerbate Inflammation in Sepsis,” Journal of Clinical Investigation 133, no. 14 (2023): e164585.

[95] W. Liu, D. H. Wu, T. Wang, et al., “CIRP Contributes to Multiple Organ Damage in Acute Pancreatitis by Increasing Endothelial Permeability,” Communication Biology 8, no. 1 (2025): 403.

[96] J. Guo, Y. Luo, J. Zuo, et al., “Echinacea Polyphenols Inhibit NLRP3-Dependent Pyroptosis, Apoptosis, and Necroptosis via Suppressing NO Production During Lipopolysaccharide-Induced Acute Lung Injury,” Journal of Agricultural and Food Chemistry 71, no. 19 (2023): 7289–7298.

[97] Z. Yang, X. Kao, L. Zhang, et al., “Exploring the Anti-PANoptosis Mechanism of Dachaihu Decoction against Sepsis-Induced Acute Lung Injury: Network Pharmacology, Bioinformatics, and Experimental Validation,” Drug Design Development and Therapy 19 (2025): 349–368.

[98] J. Huang, K. Deng, Y. Liu, et al., “Global Research Trends on Innate Lymphoid Cells in the Brain, Gut and Lung Field: A Bibliometric and Visualized Analysis,” Frontiers in Immunology 15 (2024): 1336666.

[99] X. Wang, L. Bi, J. Li, et al., “Dynamic Balance of the Lung Microbiome in Health and respiratory Diseases,” Chinese Medical Journal (2025), https://doi.org/10.1097/CM9.0000000000003712, Published online July 21, 2025.

[100] M. Ziaka and A. Exadaktylos, “Pathophysiology of Acute Lung Injury in Patients With Acute Brain Injury: The Triple-hit Hypothesis,” Critical Care 28, no. 1 (2024): 71.

[101] T. Ma, J. Liu, Z. Gao, et al., “Bone Marrow-derived Emergency Monopoiesis Drives Brain-lung Axis Injury After Traumatic Brain Injury via IL-1,” Journal of Neuroinflammation 22, no. 1 (2025): 262.

[102] W. Deng, X. Zhu, H. Li, et al., “Lung Tissue Extracellular Vesicles-Mediated Delivery of miR-128-3p as a Novel Mechanism of Acute Lung Inflammation,” International Journal of Nanomedicine 20 (2025): 4831–4848.

[103] L. Hu, L. Sun, C. Yang, et al., “Gut Microbiota-derived Acetate Attenuates Lung Injury Induced by Influenza Infection via Protecting Airway Tight Junctions,” Journal of Translational Medicine 22, no. 1 (2024): 570.

[104] S. Xiong, H. Sun, C. Lu, et al., “Kuqin Ameliorates Lipopolysaccharide-induced Acute Lung Injury by Regulating Indoleamine 2,3-dioxygenase 1 and Akkermansia Muciniphila,” Biomedicine & Pharmacotherapy 158 (2023): 114073.

[105] X. Li, W. Ding, Y. Lu, et al., “An Anti-complement Homogeneous Polysaccharide From Houttuynia cordata Ameliorates Acute Pneumonia With H1N1 and MRSA Coinfection Through Rectifying Treg/Th17 Imbalance in the Gut-lung Axis and NLRP3 Inflammasome Activation,” Acta Pharmaceutica Sinica B 15, no. 6 (2025): 3073–3091.

[106] Y. Lu, Y. Wu, M. Huang, et al., “Fuzhengjiedu Formula Exerts Protective Effect Against LPS-induced Acute Lung Injury via Gut-lung Axis,” Phytomedicine 123 (2024): 155190.

[107] H. Xiong, Y. Yang, J. Yang, et al., “Piezo2 as a Novel Biomarker of Acute respiratory Distress Syndrome Severity: A Prospective Observational Study,” Respiratory Medicine 248 (2025): 108382.

[108] M. Wang, Y. Zhang, X. Cai, et al., “Exploration and Structure-activity Relationship Research of Benzenesulfonamide Derivatives as Potent TRPV4 Inhibitors for Treating Acute Lung Injury,” Bioorganic Chemistry 147 (2024): 107396.

[109] X. Wu, S. Liu, Q. Zhao, et al., “Inhibition of TRPV4 Regulates Mitophagy through the Sirt1/FoxO1 Signaling Pathway To Alleviate Acute Lung Injury,” Inflammation 49, no. 1 (2026): 74.

[110] L. Zeng, J. Yan, N. Yi, et al., “Electroacupuncture Preconditioning Attenuates Acute Lung Injury in Mice Through Transient Receptor Potential Vanilloid 4-mediated Anti-inflammation via Inhibiting the p38 MAPK Signaling Pathway,” Histology and Histopathology 41, no. 2 (2026): 291–303.

[111] E. C. Lee and J. S. Oh, “Glymphatic Dysfunction in Neuro-Pulmonary Complications Following Subarachnoid Hemorrhage: A New Perspective on Brain-Lung Axis Disruption,” Cells 14, no. 21 (2025): 1739.

[112] V. Singh, A. Beer, A. Kraus, et al., “Stroke Increases the Expression of ACE2, the SARS-CoV-2 Binding Receptor, in Murine Lungs,” Brain Behavior and Immunity 94 (2021): 458–462.

[113] R. Wang, C. Gan, B. Gong, et al., “Tongfu Xingshen Capsule Alleviates Stroke-associated Pneumonia-induced Multiple Organ Injuries by Modulating the Gut Microbiota and Sphingolipid Metabolism,” Phytomedicine 142 (2025): 156756.

[114] F. Hou, J. Xiao, H. Wang, et al., “Alveolar Macrophage-derived TGF-β Promotes Acute Lung Injury Recovery by Regulating Inflammatory Monocyte-derived Macrophages,” Journal of Advanced Research (2025), https://doi.org/10.1016/j.jare.2025.10.075.

[115] Y. Li, J. Shi, T. Yu, et al., “FPR1-dependent Pro-inflammatory Ccl4(high) Monocytes/Macrophages Drive and Predict Sepsis-induced Acute Lung Injury,” Respiratory Research 26, no. 1 (2025): 308.

[116] M. Lin, F. Xu, Y. Deng, et al., “Large-scale Proteomic Profiling Identifies Distinct Inflammatory Phenotypes in Acute respiratory Distress Syndrome: A Multicentre, Prospective Cohort Study,” European Respiratory Journal 67, no. 2 (2026): 2500933.

[117] M. Lin, F. Xu, J. Sun, et al., “Integrative Multi-omics Analysis Unravels the Host Response Landscape and Reveals a Serum Protein Panel for Early Prognosis Prediction for ARDS,” Critical Care 28, no. 1 (2024): 213.

[118] X. Yu, Y. Song, T. Dong, et al., “Citrullination of NF-κB p65 by PAD2 as a Novel Therapeutic Target for Modulating Macrophage Polarization in Acute Lung Injury,” Advanced Science 12, no. 18 (2025): e2413253.

[119] W. Li, Z. Bao, H. Huang, et al., “Single-cell RNA Sequencing Identifies Cellular Heterogeneity in Endothelial and Epithelial Cells Associated With Nitrogen Dioxide-induced Acute Lung Injury,” Ecotoxicology and Environmental Safety 299 (2025): 118385.

[120] Y. Wei, W. Gong, Y. Wei, et al., “Decoding the lncRNA-miRNA-mRNA Network in sepsis-induced Lung Injury: From Pathogenesis to Extracellular Vesicle-based Therapy,” Frontiers in Immunology 17 (2026): 1701440.

[121] M. J. Cohen, C. B. Erickson, I. S. Lacroix, et al., “Multiomic Analyses of Longitudinal Plasma Samples Identify Thromboinflammation Endotypes and Trajectories in Patients With Trauma,” Science Translational Medicine 18, no. 836 (2026): eadw5223.

[122] T. Flerlage, D. F. Boyd, B. Clark, et al., “Integrated Longitudinal Transcriptomic and Proteomic Analysis of the Murine Lung Response to Influenza A Virus,” American Journal of Respiratory Cell and Molecular Biology (2025), https://doi.org/10.1165/rcmb.2024-0405OC.

[123] A. Demoule, Q. Fossé, A. Mercat, et al., “Operator Independent Continuous Ultrasound Monitoring of Diaphragm Excursion Predicts Successful Weaning From Mechanical Ventilation: A Prospective Observational Study,” Critical Care 28, no. 1 (2024): 245.

[124] Y. Ao, J. Ma, X. Hou, et al., “Obesity Promotes ARDS by Modulating Ceramide Transfer Protein-ceramide Pathway and Exacerbating Oxidative Stress/Apoptosis in Alveolar Macrophages,” Cellular and Molecular Life Sciences 82, no. 1 (2025): 242.

[125] H. Cui and X. Huang, “Multi-omics Integration Reveals YWHAE as a Key Mediator of Ferroptosis in ARDS,” Functional & Integrative Genomics 25, no. 1 (2025): 94.

[126] J. Fu, Z. Liu, Z. Feng, et al., “Platycodon Grandiflorum Exosome-Like Nanoparticles: The Material Basis of Fresh Platycodon Grandiflorum Optimality and Its Mechanism in Regulating Acute Lung Injury,” Journal of Nanobiotechnology 23, no. 1 (2025): 270.

[127] A. L. Barabási, N. Gulbahce, and J. Loscalzo, “Network Medicine: A Network-based Approach to human Disease,” Nature Reviews Genetics 12, no. 1 (2011): 56–68.

[128] J. Menche, A. Sharma, M. Kitsak, et al., “Disease Networks. Uncovering Disease-disease Relationships Through the Incomplete Interactome,” Science 347, no. 6224 (2015): 1257601.

[129] T. Suo, M. Xu, and J. Fang, “Lactylation Modulates Immune Infiltration in sepsis-induced Acute respiratory Distress Syndrome: A Multi-omics and Machine Learning Study With Experimental Confirmation,” European Journal of Medical Research 30, no. 1 (2025): 1100.

[130] Q. Yao, J. Wen, S. Chen, et al., “Shuangdan Jiedu Decoction Improved LPS-induced Acute Lung Injury by Regulating both cGAS-STING Pathway and Inflammasome,” Journal of Ethnopharmacology 336 (2025): 118661.

[131] Q. Xu, Y. Teng, Y. Huang, et al., “Onion-Mitochondria Inhibit Lipopolysaccharide-Induced Acute Lung Injury by Shaping Lung Macrophage Mitochondrial Function,” Advanced Science 12, no. 48 (2025): e06107.

[132] Y. Luo, J. Xu, N. He, and W. Cao, “Identification of Biomarkers for Sepsis-Induced Acute Lung Injury through Bioinformatics and Machine Learning Approaches, With Experimental Validation,” Journal of Inflammatory Research 18 (2025): 13635–13650.

[133] Y. Chang, H. J. Yoo, S. J. Kim, et al., “A Targeted Metabolomics Approach for Sepsis-induced ARDS and Its Subphenotypes,” Critical Care 27, no. 1 (2023): 263.

[134] P. Kostic, E. Zannin, M. Andersson Olerud, et al., “Positive End-expiratory Pressure Optimization With Forced Oscillation Technique Reduces Ventilator Induced Lung Injury: A Controlled Experimental Study in Pigs With Saline Lavage Lung Injury,” Critical Care 15, no. 3 (2011): R126.

[135] W. F. Pritchard, J. W. Karanian, C. Jung, et al., “In-line Miniature 3D-printed Pressure-cycled Ventilator Maintains respiratory Homeostasis in Swine With Induced Acute Pulmonary Injury,” Science Translational Medicine 14, no. 666 (2022): eabm8351.

[136] M. Zhang, L. Shang, F. Zhou, et al., “Targeting PANoptosis: A Promising Therapeutic Strategy for ALI/ARDS,” Apoptosis 30, no. 11–12 (2025): 2547–2587.

[137] X. Li, M. Wang, Y. Li, et al., “Crosstalk between Cell Death and the cGAS-STING Pathway in Sepsis-Associated Acute Lung Injury,” Journal of Inflammatory Research 18 (2025): 13291–13312.

[138] G. Long, R. Gong, Q. Wang, et al., “Role of Released Mitochondrial DNA in Acute Lung Injury,” Frontiers in Immunology 13 (2022): 973089.

[139] J. Li, M. Dong, Q. Yao, et al., “Amplifying protection against acute lung injury: Targeting both inflammasome and cGAS-STING pathway by Lonicerae Japonicae Flos-Forsythiae Fructus drug pair,” Chinese Herbal Medicines 16, no. 3 (2024): 422–434.

[140] A. Gan, J. Wang, D. Zhang, et al., “Sanzi Yangqin Decoction Alleviated Epithelial Barrier Damage in Acute Lung Injury by Mediating CD40 in Alveolar Macrophages to Inhibit Necroptosis of Pulmonary Epithelial Cells,” Phytomedicine 150 (2026): 157642.

[141] Z. Y. Kang, N. X. Xuan, Q. C. Zhou, et al., “Targeting Alveolar Epithelial Cells With Lipid Micelle-encapsulated Necroptosis Inhibitors to Alleviate Acute Lung Injury,” Communication Biology 8, no. 1 (2025): 573.

[142] B. Ye, Y. Jin, S. Hu, et al., “Spermidine Alleviates Sepsis-Induced Acute Lung Injury Through AMPK-Mediated Improvement of Necroptosis,” Inflammation 49, no. 1 (2025): 9.

[143] J. Wei, Z. Liu, H. Sun, and L. Xu, “Perillaldehyde Ameliorates Lipopolysaccharide-induced Acute Lung Injury via Suppressing the cGAS/STING Signaling Pathway,” International Immunopharmacology 130 (2024): 111641.

[144] F. Hou, N. Shi, H. Yuan, et al., “Targeting Alveolar Macrophages: A Promising Intervention for Pulmonary Infection and Acute Lung Injury,” Cellular & Molecular Biology Letters 30, no. 1 (2025): 69.

[145] W. Yang, H. Liu, X. Liu, et al., “Biomimetic Fucoidan Nanoparticles With Regulation of Macrophage Polarization for Targeted Therapy of Acute Lung Injury,” Carbohydrate Polymers 351 (2025): 122967.

[146] Y. Zhao, X. Zhu, L. Hu, et al., “Macrophage Membrane-coated Polydopamine Nanomedicine for Treating Acute Lung Injury Through Modulation of Neutrophil Extracellular Traps and M2 Macrophage Polarization,” Materials Today Bio 32 (2025): 101708.

[147] B. Tan, W. Yang, G. Zhang, and R. Zeng, “Apoptotic-body-inspired Nanoplatform Targeting the Lung-macrophage-mitochondrial Axis for Acute Lung Injury Therapy,” Journal of Controlled Release 389 (2026): 114413.

[148] C. Ma, Z. Yang, J. Wang, et al., “Inhalable Targeted CD8 + T Cell Nanoparticles Loaded Ferroptosis Inhibitor Ferrostatin-1 Alleviate Acute Lung Injury,” Journal of Nanobiotechnology 23, no. 1 (2025): 723.

[149] L. Wang, L. Zhao, J. Lv, et al., “BLT1-dependent Alveolar Recruitment of CD4(+)CD25(+) Foxp3(+) Regulatory T Cells Is Important for Resolution of Acute Lung Injury,” American Journal of Respiratory and Critical Care Medicine 186, no. 10 (2012): 989–998.

[150] S. Li, W. Zhuang, Y. Wang, et al., “CXCR1 Depletion in Ly6C(+) cDC2 Alleviates Acute Lung Injury via Modulation of Th17/Treg Balance,” Advanced Science 41 (2025): e06287.

[151] S. Luo, Q. Zhang, W. Zhou, et al., “METTL3 promotes Neutrophil Extracellular Trap Formation via SYK/ERK/MEK Signaling During Acute Lung Injury,” Journal of Advanced Research (2026), https://doi.org/10.1016/j.jare.2026.01.044, Published online January 22, 2026.

[152] P. Y. Liu, C. Y. Chen, Y. L. Lin, et al., “RNF128 regulates Neutrophil Infiltration and Myeloperoxidase Functions to Prevent Acute Lung Injury,” Cell Death & Disease 14, no. 6 (2023): 369.

[153] Y. Fujita, T. Kadota, R. Kaneko, et al., “Mitigation of Acute Lung Injury by human Bronchial Epithelial Cell-derived Extracellular Vesicles via ANXA1-mediated FPR Signaling,” Communication Biology 7, no. 1 (2024): 514.

[154] S. Y. Chen, Y. L. Chen, P. C. Li, et al., “Engineered Extracellular Vesicles Carrying Let-7a-5p for Alleviating Inflammation in Acute Lung Injury,” Journal of Biomedical Science 31, no. 1 (2024): 30.

[155] L. Xia, C. Zhang, N. Lv, et al., “AdMSC-derived Exosomes Alleviate Acute Lung Injury via Transferring Mitochondrial Component to Improve Homeostasis of Alveolar Macrophages,” Theranostics 12, no. 6 (2022): 2928–2947.

[156] J. Kim, D. Seo, S. Y. Yoo, et al., “Lung-homing nanoliposomes for early intervention in NETosis and inflammation during acute lung injury,” Nano Convergence 12, no. 1 (2025): 8.

[157] D. Lei, L. L, and T. Qin, “Reprogramming Lung Redox Homeostasis by NIR Driven Ultra-Small Pd Loaded Covalent Organic Framework Inhibits NF-κB Pathway for Acute Lung Injury Immunotherapy,” Advanced Science 12, no. 14 (2025): e2413697.

[158] H. Xing, X. Bai, X. Pei, et al., “Synergistic Anti-oxidative/Anti- inflammatory Treatment for Acute Lung Injury With Selenium Based Chlorogenic Acid Nanoparticles Through Modulating Mapk8ip1/MAPK and Itga2b/PI3k-AKT Axis,” Journal of Nanobiotechnology 23, no. 1 (2025): 37.

[159] T. Cao, A. Q. Li, Y. Zhang, et al., “Norwogonin Attenuates LPS-induced Acute Lung Injury Through Inhibiting Src/AKT1/NF-κB Signaling Pathway,” Phytomedicine 139 (2025): 156432.

[160] Z. Cao, H. Rao, W. Yang, et al., “Luteolin Mitigates Acute Lung Injury through Immune Modulation and Antinecroptosis Effects by Targeting the BTK and FLT3 Signaling Pathways,” Journal of Agricultural and Food Chemistry 73, no. 9 (2025): 5180–5193.

[161] T. Liu, C. Tian, H. Li, et al., “Therapeutic Potential of Inosine in Acute Lung Injury: Mechanistic Insights Into TLR4 Suppression and Macrophage Polarization,” Phytomedicine 143 (2025): 156854.

[162] H. Bao-Yuan, L. Shu-Ru, C. Le-Xin, et al., “Shikonin Ameliorated LPS-induced Acute Lung Injury in Mice via Modulating MCU-mediated Mitochondrial Ca(2+) and Macrophage Polarization,” Phytomedicine 135 (2024): 156043.

[163] Y. H. Wu, Q. L. Zhang, S. Y. Mai, et al., “Strictosamide Alleviates Acute Lung Injury via Regulating T Helper 17 Cells, Regulatory T Cells, and Gut Microbiota,” Phytomedicine 128 (2024): 155490.

[164] A. Gu, B. Wang, Y. Zhang, et al., “SENP6 Restrains NLRP3 Inflammasome Activation via DeSUMOylation-Driven K48-Linked Ubiquitination of NLRP3 in Acute Lung Injury,” Research (Wash D C) 9 (2026): 1069.

[165] J. Zhang, Y. Guo, M. Mak, and Z. Tao, “Translational Medicine for Acute Lung Injury,” Journal of Translational Medicine 22, no. 1 (2024): 25.

[166] H. Liu, J. Dong, C. Xu, et al., “Acute Lung Injury: Pathogenesis and Treatment,” Journal of Translational Medicine 23, no. 1 (2025): 926.

[167] Y. Liu, K. Wang, F. Gao, et al., “Engineering Biomimetic Nanoplatforms for Acute Lung Injury: From Mechanistic Insights to Translational Opportunities,” International Journal of Nanomedicine 20 (2025): 14201–14218.

[168] E. Obeng, A. Ergashev, Q. Yao, et al., “Bioactive Nanomaterials: Comprehensive Monitoring and Regulation of Acute Pancreatitis Induced Acute Lung Injury,” International Journal of Nanomedicine 20 (2025): 9517–9558.

[169] Y. Zhang, W. Sun, M. Wang, et al., “Application of Nanoparticles in the Treatment of Acute Lung Injury: Current Situation and Future Directions,” Materials Today Bio 34 (2025): 102199.

[170] Y. Zheng, Y. Zhao, S. Zhang, et al., “Advances in Natural Product-based Nanoparticles for the Treatment of Acute Lung Injury,” Materials Today Bio 35 (2025): 102486.

[171] Z. Gu, W. Xue, G. Mao, et al., “Native and Engineered Extracellular Vesicles for the Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome,” Small Science 5, no. 6 (2025): 2400606.

[172] G. Li, B. Jin, J. Zhou, et al., “Mechanisms and Nanomedicine Interventions of Acute Lung Injury Induced by Intestinal Ischemia-Reperfusion: A Mini Review,” International Journal of Nanomedicine 20 (2025): 9347–9367.

[173] S. Chen, E. Chen, J. Su, et al., “Magnetically Navigated Nano-PROTAC Ameliorates Acute Lung Injury,” Journal of Nanobiotechnology 23, no. 1 (2025): 622.

[174] W. Fan, Y. Tang, Y. Liu, et al., “ROS-responsive Nanoparticles for Bioimaging and Treating Acute Lung Injury by Releasing Dexamethasone and Improving Alveolar Macrophage Homeostasis,” Journal of Nanobiotechnology 22, no. 1 (2024): 729.

[175] D. Xia, Z. Lu, S. Li, et al., “Development of an Intelligent Reactive Oxygen Species-Responsive Dual-Drug Delivery Nanoplatform for Enhanced Precise Therapy of Acute Lung Injury,” International Journal of Nanomedicine 19 (2024): 2179–2197.

[176] Z. Zhai, W. Ouyang, Y. Yao, et al., “Dexamethasone-loaded ROS-responsive Poly(thioketal) Nanoparticles Suppress Inflammation and Oxidative Stress of Acute Lung Injury,” Bioactive Materials 14 (2022): 430–442.

[177] M. Ji, H. Liu, M. Wei, et al., “Redox-sensitive Disulfide-bridged Self-assembled Nanoparticles of Dexamethasone With High Drug Loading for Acute Lung Injury Therapy,” International Journal of Pharmacology 664 (2024): 124600.

[178] C. Jin, Y. Zhang, L. Chen, et al., “Lung Epithelial Cell Membrane-Camouflaged ROS-Activatable Berberine Nanoparticles for Targeted Treatment in Acute Lung Injury,” International Journal of Nanomedicine 20, no. 202: 6163–6183.

[179] R. Wang, Q. Li, P. Wu, et al., “Fe-Capsaicin Nanozymes Attenuate Sepsis-Induced Acute Lung Injury via NF-κB Signaling,” International Journal of Nanomedicine 19 (2024): 73–90.

[180] J. Yan, Z. Tang, Y. Li, et al., “Molybdenum Nanodots for Acute Lung Injury Therapy,” ACS Nano 17, no. 23 (2023): 23872–23888.

[181] M. Wang, K. Wang, G. Deng, et al., “Mitochondria-Modulating Porous Se@SiO(2) Nanoparticles Provide Resistance to Oxidative Injury in Airway Epithelial Cells: Implications for Acute Lung Injury,” International Journal of Nanomedicine 15 (2020): 2287–2302.

[182] J. Yan, X. Meng, Y. Zhu, et al., “Remodeling the Blood-air Barrier and Enhancing the Pulmonary Microcirculation With a Dual-responsive Biomimetic Nanosystem for Precise Therapy in Acute Lung Injury,” Acta Biomaterialia 202 (2025): 573–590.

[183] F. Y. Yang, J. Wang, X. P. Fan, et al., “Development of NIR-II Ratiometric Fluorescent Nanoprobe for HClO Imaging in Acute Lung Injury,” Advanced Healthcare Materials 14, no. 20 (2025): e2402264.

[184] C. Li, R. Huang, K. Ma, et al., “Specific Lung-Targeting Shortwave Infrared Luminescence Nanoprobe: Precisely Delineating Sepsis-Induced Acute Lung Injury,” Analytical Chemistry 97, no. 35 (2025): 19294–19305.

[185] X. Lin, Q. F. Meng, Y. Pan, et al., “Inhalable Macrophage Membrane-Camouflaged Hyperbranched Polymeric Nanoparticles for Acute Lung Injury Treatment,” Nano Letters 25, no. 34 (2025): 13003–13013.

[186] X. Li, Z. Tang, L. Kuang, Y. Wu, and X. Huang, “Platelet Membrane-coated Nanoparticles Inhibit Platelet Activation and Neutrophil Extracellular Traps Formation in Acute Lung Injury,” Journal of Translational Medicine 23, no. 1 (2025): 841.

[187] W. Bai, S. Chen, T. Liu, et al., “Dual-action Membrane-chimeric Liposomes With Self-reinforcing Targeting for Acute Lung Injury Treatment,” Journal of Controlled Release 383 (2025): 113820.

[188] Q. Li, H. Sun, X. Zhang, et al., “Engineered Biomimetic Nanomicelles Target Inflammation in Sepsis-Associated Acute Lung Injury by Scavenging ROS and Reprogramming Macrophages,” International Journal of Nanomedicine 20 (2025): 15827–15845.

[189] Z. C. Sun, R. Liao, C. Xian, et al., “Natural Pachypodol Integrated, Lung Targeted and Inhaled Lipid Nanomedicine Ameliorates Acute Lung Injury via Anti-inflammation and Repairing Lung Barrier,” Journal of Controlled Release 375 (2024): 300–315.

[190] R. Liao, Z. C. Sun, L. Wang, et al., “Inhalable and Bioactive Lipid-nanomedicine Based on bergapten for Targeted Acute Lung Injury Therapy via Orchestrating Macrophage Polarization,” Bioactive Materials 43 (2025): 406–422.

[191] J. Li, Y. Hu, S. Chen, et al., “Nanoparticle-Mediated “Cut-Off and Clean-Up” Strategy for Neutrophil Manipulation in Acute Lung Injury Therapy,” ACS Nano 19, no. 37 (2025): 33372–33386.

[192] Z. E. Hu, F. Z. Zhang, and M. Zeng, “Inhalable Food-Grade MOFs Loaded Gas Messenger for Acute Lung Injury Treatment by Pulmonary Delivery,” ACS Applied Materials & Interfaces 17, no. 51 (2025): 70093–70109.

[193] Y. Wen, Y. Teng, S. Zheng, et al., “Enhanced Bioavailability of Anemoside B4 by Dry Powder Inhalation Mitigates High-altitude Acute Lung Injury,” Phytomedicine 152 (2026): 157788.

[194] R. Zhao, L. Wang, T. Wang, et al., “Inhalation of MSC-EVs Is a Noninvasive Strategy for Ameliorating Acute Lung Injury,” Journal of Controlled Release 345 (2022): 214–230.

[195] G. Zhang, H. Liang, G. Zhang, et al., “Low-concentration cholesterol modification enhances Clematis filamentosa Dunn-derived extracellular vesicle-mediated macrophage polarization regulation for acute lung injury therapy,” RSC Advances 16, no. 7 (2026): 5941–5955.

[196] Q. Zhao, J. Lai, Y. Jiang, et al., “Lactiplantibacillus Plantarum -derived Extracellular Vesicles Alleviate Acute Lung Injury by Inhibiting Ferroptosis of Macrophages,” Journal of Nanobiotechnology 23, no. 1 (2025): 307.

[197] C. Ma, Z. Yang, J. Wang, et al., “Double-Responsive Macrophage-Derived Exosomes Alleviate Acute Lung Injury,” Biomaterials Research 29 (2025): 0277.

[198] Y. Tao, X. Xu, B. Yang, et al., “Mitigation of Sepsis-Induced Acute Lung Injury by BMSC-Derived Exosomal miR-125b-5p through STAT3-Mediated Suppression of Macrophage Pyroptosis,” International Journal of Nanomedicine 18 (2023): 7095–7113.

[199] Y. Wang, J. Huang, Y. An, et al., “Magnetic Engineered Bone Mesenchymal Stem Cells-derived Exosomes for Targeted Acute Lung Injury Therapy,” Stem Cell Research & Therapy 16, no. 1 (2025): 539.

[200] G. Liang, M. Zeng, Q. Wang, et al., “Exosomal miR-218 Secreted From Endothelial Progenitor Cells Mitigates Acute Lung Injury in sepsis Mice by Inhibiting HMGA1 in Alveolar Macrophages,” Stem Cell Research & Therapy 16, no. 1 (2025): 431.

[201] W. Lai, S. Ahan, Z. Ying, and W. Jiang, “HUVEC-derived Exosomes Alleviate Lipopolysaccharide-induced Acute Lung Injury Inflammation by Restoring the Balance of Mitochondrial Fusion and Division,” Cellular and Molecular Life Sciences 83, no. 1 (2026): 92.

[202] L. Yin, X. Zhang, Y. Zhou, et al., “Hypoxic TCs-preconditioned MSCs Ameliorate Acute Lung Injury via Enhanced Treg Recruitment and Function Through CXCL5/6-CXCR1 Axis,” Stem Cell Research & Therapy 17, no. 1 (2025): 54.

[203] L. Tian, J. Jin, F. Lai, et al., “Nebulized M2 Macrophage-derived Nanovesicles for the Treatment of Explosion-induced Acute Lung Injury,” Journal of Colloid and Interface Science 691 (2025): 137381.

[204] L. Tan, C. Zhang, X. Kou, et al., “Apoptotic Vesicles Attenuate Acute Lung Injury via CD73-Mediated Inhibition of Platelet Activation and NETosis,” International Journal of Nanomedicine 20 (2025): 91–107.

[205] K. Sriram, M. B. Insel, and P. A. Insel, “Inhaled β2 Adrenergic Agonists and Other cAMP-Elevating Agents: Therapeutics for Alveolar Injury and Acute Respiratory Disease Syndrome?,” Pharmacological Reviews 73, no. 4 (2021): 488–526.

[206] Y. Li, J. Zhao, J. Wei, et al., “Neutrophil Elastase Inhibitor (Sivelestat) in the Treatment of Acute respiratory Distress Syndrome Induced by COVID-19: A Multicenter Retrospective Cohort Study,” Respiratory Research 26, no. 1 (2025): 28.

[207] M. G. Matera, P. Rogliani, J. Ora, et al., “A Comprehensive Overview of Investigational Elastase Inhibitors for the Treatment of Acute respiratory Distress Syndrome,” Expert Opinion on Investigational Drugs 32, no. 9 (2023): 793–802.

[208] T. Pan, T. Tuoerxun, X. Chen, et al., “The Neutrophil Elastase Inhibitor, sivelestat, Attenuates Acute Lung Injury in Patients With Cardiopulmonary Bypass,” Frontiers in Immunology 14 (2023): 1082830.

[209] X. Chen, J. Shen, X. Jiang, et al., “Characterization of Dipyridamole as a Novel Ferroptosis Inhibitor and Its Therapeutic Potential in Acute respiratory Distress Syndrome Management,” Theranostics 14, no. 18 (2024): 6947–6968.

[210] L. Rein, K. Calero, R. Shah, et al., “Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome,” Critical Care Medicine 50, no. 12 (2022): 1701–1713.

[211] A. Neubauer, J. Johow, E. Mack, et al., “The Janus-kinase Inhibitor Ruxolitinib in SARS-CoV-2 Induced Acute respiratory Distress Syndrome (ARDS),” Leukemia 35, no. 10 (2021): 2917–2923.

[212] M. A. Matthay, H. Zhou, A. Sarma, et al., “Treatment With Allogenic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome: A Double-Blind, Placebo-controlled, Multi-Center, Phase 2b Clinical Trial (STAT),” American Journal of Respiratory and Critical Care Medicine 212, no. 3 (2026): 428–439, https://doi.org/10.1164/rccm.202411-2254OC, Published online July 29, 2025.

[213] Y. Wu, R. Xu, Y. Li, et al., “Efficacy and Safety of Mesenchymal Stem/Stromal Cells and Their Derived Extracellular Vesicles for Acute respiratory Distress Syndrome: A Systematic Review and Meta-analysis,” Stem Cell Research & Therapy 16, no. 1 (2025): 522.

[214] A. Duong, P. Giguère, R. Shorr, and D. S. Allan, “A Systematic Review of Published Clinical Studies Using Cell-derived Extracellular Vesicles: A Focus on Efficacy in COVID-19 and Wound Healing,” Current Research Translational Medicine 74, no. 1 (2025): 103557.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.